Cost-effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden
Granstrom O, Bergenheim K, McEwan P, Sennfalt K, Henriksson M

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
22001114

DOI
10.1016/j.pcd.2011.09.003

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Adamantane /adverse effects /analogs & derivatives /economics /therapeutic use; Biomarkers /blood; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2 /blood /complications /drug therapy /economics /mortality; Dipeptides /adverse effects /economics /therapeutic use; Dipeptidyl-Peptidase IV Inhibitors /adverse effects /economics /therapeutic use; Drug Costs; Drug Therapy, Combination; Female; Hemoglobin A, Glycosylated /metabolism; Humans; Male; Metformin /economics /therapeutic use; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Sulfonurea Compounds /economics /therapeutic use; Sweden /epidemiology; Time Factors; Treatment Outcome

AccessionNumber
22012021424

Date bibliographic record published
29/11/2012